About Amit Khera, MD

Dr. Amit Khera received his BS in Biology and Neurosciences from Duke University in 2005, graduating summa cum laude. He received his MD with Alpha Omega Alpha honors from the Perelman School of Medicine at the University of Pennsylvania in 2010. He completed his internship and residency in internal medicine at the Brigham and Women's Hospital, Harvard Medical School in 2013. He completed his clinical and research fellowship in cardiovascular medicine at the Massachusetts General Hospital, Harvard Medical School in 2016. 

Dr. Khera is a physician-scientist with expertise in epidemiology, clinical medicine, and human genetics. Among his scientific contributions, he pioneered a new approach to quantify genetic risk for common diseases, developed biomarkers that provide new biologic insights, and analyzed large-scale gene sequencing data to highlight key pathways underlying risk for coronary artery disease. His research program uses genetic variation as a tool to uncover new biology and enable enhanced clinical care informed by inherited susceptibility.

In addition to his research efforts, Dr. Khera is a clinical cardiologist within the Corrigan Minehan Heart Center focusing on heart attack prevention, genomic medicine, and cardiac rehabilitation.

Departments, Centers, & Programs:

Clinical Interests:

Treats:

Locations

Cardiovascular Disease Prevention Center
25 New Chardon Street
Suite 301
Boston, MA 02114-4774
617-726-1843
Fax: 617-726-2203

Medical Education

  • MD, University of Pennsylvania School of Medicine
  • Residency, Brigham and Women's Hospital
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Internal Medicine, American Board of Internal Medicine
  • Cardiovascular Disease, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Publications

  • View my most recent publications at PubMed

    Select Publications:

    • Khera AV, Won HH, Peloso GM, et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol. 2016;67(22):2578-89.
    • Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation. 2014;11;129(6):635-42.
    • Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364(2):127-35.